Trial Profile

A Biomarker-directed Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Whose Disease Has Progressed on First-Line Osimertinib Therapy

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 06 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Carboplatin (Primary) ; Durvalumab (Primary) ; Gefitinib (Primary) ; Necitumumab (Primary) ; Pemetrexed (Primary) ; Savolitinib (Primary) ; Alectinib; Osimertinib; Selpercatinib
Indications Adenocarcinoma; Non-small cell lung cancer
Focus Biomarker; Therapeutic Use
Acronyms ORCHARD
Sponsors AstraZeneca

Most Recent Events

25 Mar 2025 Results presented in an AstraZeneca media release
25 Mar 2025 According to an AstraZeneca media release, data from this trial presented at the European Lung Cancer Congress (ELCC) 2025, 26 to 29 March.
02 Feb 2024 Planned End Date changed from 31 Dec 2025 to 6 May 2025.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com